Examining Vitamin B12 Metabolism in Children with Sickle Cell Disease Using MEOPA
Study of Vitamin B12 Metabolism in Children With Sickle Cell Disease Exposed to MEOPA , a Prospective Study at Reims University Hospital
CHU de Reims · NCT06581900
This study is testing how a medical gas used for pain relief affects vitamin B12 levels in children with sickle cell disease to see if it impacts their health.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 29 (estimated) |
| Ages | 2 Years to 18 Years |
| Sex | All |
| Sponsor | CHU de Reims (other) |
| Locations | 1 site (Reims) |
| Trial ID | NCT06581900 on ClinicalTrials.gov |
What this trial studies
This observational study investigates how exposure to MEOPA, a medical gas used for pain relief in sickle cell disease patients, affects vitamin B12 metabolism in children aged 2 to 18. The study hypothesizes that prolonged exposure to MEOPA leads to a functional deficiency of vitamin B12, which is crucial for DNA production and myelin sheath formation. By analyzing the metabolic changes in vitamin B12 levels, researchers aim to understand the implications for sickle cell disease management. Participants will be monitored for their vitamin B12 levels and related health outcomes.
Who should consider this trial
Good fit: Ideal candidates for this study are children aged 2 to 18 years diagnosed with sickle cell disease who are affiliated with social security.
Not a fit: Patients with pre-existing neurological defects or those unwilling to participate in blood or data collection may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to improved management strategies for vitamin B12 deficiency in children with sickle cell disease.
How similar studies have performed: While there have been studies on vitamin B12 metabolism in sickle cell disease, the specific focus on MEOPA's impact is relatively novel.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Sickle cells patient * Age between 2 and 18 years old * Being affiliated with social security Exclusion Criteria: * Having a neurological defect prior to the study * Being against the collection of blood or data
Where this trial is running
Reims
- Chu Reims — Reims, France (RECRUITING)
Study contacts
- Study coordinator: Claire PLUCHART, MD
- Email: cpluchart@chu-reims.fr
- Phone: 0326783357
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions: Sickle Cells Patients